GT Biopharma is trading 6.4% down at $4.25, with biotech-sector weakness the clearest explanation. - The biotech ETF was down 5.19% during the regular session, while broader market indices were higher. - No new company-specific announcement explaining the decline appeared in the search. - The company’s previously announced SITC presentation is scheduled for November 6; it is not a newly reported catalyst.